New pill targets tough cancers: first human trial begins

NCT ID NCT07458347

Recruiting now Disease control Sponsor: Kestrel Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated May 03, 2026 · Updated 8 times

Summary

This early-stage study tests a new oral drug, KST-6051, in adults with advanced lung, pancreatic, colorectal, or other solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 145 participants who have not responded to standard treatments will take the drug, and researchers will monitor side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Sidney Kimmel Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.

KRAS-MUTANT COLORECTAL CANCER (CRC) KRAS-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) OTHER KRAS-MUTANT SOLID TUMORS